Patents by Inventor Alessandra Vitelli

Alessandra Vitelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220305120
    Abstract: Simian adenoviral vectors are formulated with bioadhesives and excipients that maintain immunogenicity. They can be administered mucosally to provide effective prophylaxis and therapy.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 29, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Simona GALLORINI, Federico NAPOLITANO, Alessandra VITELLI
  • Publication number: 20220220157
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: January 25, 2022
    Publication date: July 14, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
  • Publication number: 20220112245
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 14, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI, Benjamin WIZEL
  • Patent number: 11268108
    Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 8, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefano Colloca, Alessandra Vitelli
  • Patent number: 11254711
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Fabiana Grazioli, Alfredo Nicosia, Alessandra Vitelli
  • Publication number: 20210269486
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.
    Type: Application
    Filed: December 8, 2017
    Publication date: September 2, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Virginia AMMENDOLA, Stefaano COLLOCA, Alessandra VITELLI, Benjamin Wizel
  • Publication number: 20210189421
    Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI
  • Publication number: 20210154290
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 27, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • Publication number: 20210069322
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 11, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • Publication number: 20210060150
    Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
    Type: Application
    Filed: August 6, 2020
    Publication date: March 4, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20200360509
    Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.
    Type: Application
    Filed: February 25, 2020
    Publication date: November 19, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20200140886
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 7, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
  • Publication number: 20180256704
    Abstract: Administration regimens suitable for vaccine compositions comprising polynucleotides encoding immunogenic polypeptides. Such administration regimens involve the repeated administration of a vaccine composition.
    Type: Application
    Filed: November 1, 2017
    Publication date: September 13, 2018
    Inventors: Alfredo NICOSIA, Ricardo CORTESE, Alessandra VITELLI
  • Publication number: 20180216081
    Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
    Type: Application
    Filed: July 25, 2016
    Publication date: August 2, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20170143820
    Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.
    Type: Application
    Filed: June 12, 2015
    Publication date: May 25, 2017
    Applicant: GLAXOSMITHKLINE SA
    Inventors: Ann-Muriel STEFF, Jean-Francois TOUSSAINT, Alessandra VITELLI
  • Publication number: 20170049879
    Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 23, 2017
    Inventors: Alessandra VITELLI, Alfredo NICOSIA, Ricardo CORTESE
  • Publication number: 20150209420
    Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve, the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 30, 2015
    Inventors: Alfredo Nicosia, Ricardo Cortese, Alessandra Vitelli
  • Publication number: 20140141042
    Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).
    Type: Application
    Filed: December 30, 2011
    Publication date: May 22, 2014
    Applicant: OKAIROS AG
    Inventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
  • Patent number: 7928193
    Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: April 19, 2011
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
  • Publication number: 20080286275
    Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.
    Type: Application
    Filed: July 1, 2005
    Publication date: November 20, 2008
    Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli